{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Bone+Disease",
    "query": {
      "condition": "Metabolic Bone Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1112,
    "total_pages": 112,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Bone+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:46:00.512Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01928082",
      "title": "The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercalciuria",
        "Hypercalciuria, Familial Idiopathic",
        "Osteopenia",
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Transdermal estradiol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "69 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 69 Years · Female only"
      },
      "enrollment_count": 1,
      "start_date": "2013-08-01",
      "completion_date": "2014-08-01",
      "has_results": true,
      "last_update_posted_date": "2018-12-10",
      "last_synced_at": "2026-05-22T09:46:00.512Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01928082"
    },
    {
      "nct_id": "NCT02020941",
      "title": "Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Attaya Suvannasankha",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2013-09",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-05-22T09:46:00.512Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02020941"
    },
    {
      "nct_id": "NCT00417612",
      "title": "Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypophosphatemia, Familial",
        "Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "Paricalcitol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2007-01",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2020-03-17",
      "last_synced_at": "2026-05-22T09:46:00.512Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00417612"
    },
    {
      "nct_id": "NCT00000430",
      "title": "Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteopenia",
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Alendronate",
          "type": "DRUG"
        },
        {
          "name": "Estrogen/progestin therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "60 Years and older · Female only"
      },
      "enrollment_count": 240,
      "start_date": "1999-10",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2007-01-04",
      "last_synced_at": "2026-05-22T09:46:00.512Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000430"
    },
    {
      "nct_id": "NCT00609830",
      "title": "GIOP Prevention Among People With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoporosis",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Tailored Materials",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Tailored Materials Plus Physician Feedback",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Generic Materials",
          "type": "BEHAVIORAL"
        },
        {
          "name": "No Information",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 273,
      "start_date": "2001-07",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2015-06-16",
      "last_synced_at": "2026-05-22T09:46:00.512Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00609830"
    },
    {
      "nct_id": "NCT02125877",
      "title": "Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Iron Overload Due to Transfusion-dependant Anemias"
      ],
      "interventions": [
        {
          "name": "Deferasirox dispersible tablet",
          "type": "DRUG"
        },
        {
          "name": "Defearisox film-coated tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 173,
      "start_date": "2014-07-08",
      "completion_date": "2016-02-24",
      "has_results": true,
      "last_update_posted_date": "2017-07-25",
      "last_synced_at": "2026-05-22T09:46:00.512Z",
      "location_count": 5,
      "location_summary": "Orange, California • Chicago, Illinois • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02125877"
    },
    {
      "nct_id": "NCT04551170",
      "title": "Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pseudohypoparathyroidism",
        "Albright Hereditary Osteodystrophy",
        "Pseudohypoparathyroidism Type 1a"
      ],
      "interventions": [
        {
          "name": "Theophylline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Years to 12 Years"
      },
      "enrollment_count": 34,
      "start_date": "2020-07-13",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-05-22T09:46:00.512Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04551170"
    },
    {
      "nct_id": "NCT06164951",
      "title": "A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Achondroplasia"
      ],
      "interventions": [
        {
          "name": "Infigratinib 0.25 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator 0.25 mg/kg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 114,
      "start_date": "2023-11-10",
      "completion_date": "2025-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-05-22T09:46:00.512Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06164951"
    },
    {
      "nct_id": "NCT06830005",
      "title": "Validating Osteoporosis Detection in Rho AI Software",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteopenia or Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Rho AI software",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 800,
      "start_date": "2025-06-01",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-05-22T09:46:00.512Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06830005"
    },
    {
      "nct_id": "NCT02155595",
      "title": "Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Osteoporosis",
        "Atypical Femoral Fractures",
        "Prodromal Bone Deterioration"
      ],
      "interventions": [
        {
          "name": "500 without BP treatment",
          "type": "OTHER"
        },
        {
          "name": "500 with BP treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "50 Years and older · Female only"
      },
      "enrollment_count": 738,
      "start_date": "2014-05",
      "completion_date": "2018-08-31",
      "has_results": false,
      "last_update_posted_date": "2019-03-29",
      "last_synced_at": "2026-05-22T09:46:00.512Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02155595"
    }
  ]
}